Background.: For many decades dicoumarols are employed for prophylaxis and therapy of thromboembolic diseases. For some of these diseases new, efficacious, and safe oral anticoagulant drugs (NAO) are now available: dabigatran, rivaroxaban, apixaban. The Italian Agency for drugs (AIFA) regulates their refund by Public Health System. In non-valvular atrial fibrillation (FANV) a sufficient condition for repayment is a Time in Therapeutic Range (TTR) in dicumarols below 61% for rivaroxaban and 71% for dabigatran and apixaban. In our Anticoagulation clinic (centro FCSA 186, Federation of Anticoagulation clinics) we are following about 1000 patients in anticoagulant therapy (TAO); for about 350 more patients our Laboratory Service only assays the prothrombin time (PT), the patients being followed by their own family physicians. From regional database we estimate that about 11400 patients are taking TAO for FANV in our territory (ULSS 20), 11% of them followed by FCSA, and about 113000 in our region (Veneto), 20% followed by FCSA.
|Titolo:||Quality of therapy with dicoumarols, new oral anticoagulants, and role of anticoagulation clinics [Qualità della terapia con dicumarolici, nuovi anticoagulanti orali, e ruolo dei centri per la terapia anticoagulante]|
|Data di pubblicazione:||2014|
|Appare nelle tipologie:||01.01 Articolo in Rivista|